CRISPR Therapeutics, Inc.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary

Employees: -

Market Cap: $4.1B

Website

Clinical Trials

A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed/Refractory Hematologic Malignancies

Phase 1

Recruiting

Conditions: Acute Myeloid Leukemia
T Cell Lymphoma
B Cell Lymphoma

Interventions: Biological: CTX131

First Posted Date: 2024-07-09

Last Posted Date: 2024-11-29

Lead Sponsor: CRISPR Therapeutics

Target Recruit Count: 290

Registration Number: NCT06492304

Locations: 🇺🇸
Research Site 2, Bronx, New York, United States
🇺🇸
Research Site 6, Phoenix, Arizona, United States
🇺🇸
Research Site 5, Stanford, California, United States

and more 3 locations

Prev
1
Next

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy